<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Genetic variation in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) receptor 2 gene (TNFRSF1B) has shown association with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo>, <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, and essential <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we tested the TNFRSF1B marker used in the latter studies in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A case-control study of a microsatellite marker with five alleles (CA13- CA17) in intron 4 of TNFRSF1B was performed in 357 well-characterized white patients and 183 healthy control subjects </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The CA16 allele was associated with clinical <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (frequency = 27% in 69 patients with the condition versus 16% in 230 subjects without the condition; chi2 = 9.0, P = 0.011; odds ratio = 2.1 [95% CI 1.2-3.8]) </plain></SENT>
<SENT sid="4" pm="."><plain>No association was seen with other complications or <z:mp ids='MP_0002055'>diabetes</z:mp> itself </plain></SENT>
<SENT sid="5" pm="."><plain>The CA16 allele tracked with elevation plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (1.3 +/- 0.2, 1.2 +/- 0.4, and 1.1 +/- 0.2 for CA16/CA16, CA16/-, and -/-, respectively; n = 9, 110, and 218, respectively; P = 0.009) and reduction in plasma glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (6.6 +/- 0.3, 8.3 +/- 0.2, and 8.1 +/- 0.1 for CA16/CA16, CA16/-, and -/-, respectively; n = 9, 102, 205, respectively; P = 0.007) Significance remained after Bonferroni correction for multiple testing </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Genetic variation in or near TNFRSF1B may predispose clinical <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, reduced glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, and increased <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="7" pm="."><plain>The latter could be part of a protective response </plain></SENT>
</text></document>